Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.43 |
| ▸ | MGLL | Q99685 | 4/20 | 0.42 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.40 |
| ▸ | CTSS | P25774 | 1/20 | 0.40 |
| ▸ | CTSK | P43235 | 1/20 | 0.40 |
| ▸ | MMP1 | P03956 | 1/20 | 0.39 |
| ▸ | MMP13 | P45452 | 1/20 | 0.39 |
| ▸ | EED | O75530 | 1/20 | 0.39 |
| ▸ | RBBP4 | Q09028 | 1/20 | 0.39 |
| ▸ | SUZ12 | Q15022 | 1/20 | 0.39 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.39 |
| ▸ | AEBP2 | Q6ZN18 | 1/20 | 0.39 |
| ▸ | NOTCH1 | P46531 | 1/20 | 0.39 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6750022 | 0.92 | GPR119 (0.43) | GPR119MGLLUSP30CTSSCTSK | |
| SCHEMBL6751490 | 0.90 | GPR119 (0.45) | GPR119MGLLUSP30 | |
| SCHEMBL6751810 | 0.89 | MGLL (0.41) | MGLLUSP30 | |
| SCHEMBL6751489 | 0.88 | CETP (0.37) | — | |
| SCHEMBL7041662 | 0.85 | MGLL (0.42) | MGLLUSP30 | |
| SCHEMBL7031551 | 0.83 | MCHR1 (0.43) | CTSSCTSK | |
| SCHEMBL6318034 | 0.79 | KDM4E (0.46) | GPR119MGLLNOTCH1 | |
| SCHEMBL7038825 | 0.79 | NOTCH1 (0.44) | GPR119MGLLNOTCH1PTPN2PTPN1 | |
| SCHEMBL6831982 | 0.78 | NOTCH1 (0.41) | GPR119MGLLUSP30NOTCH1PTPN2 | |
| SCHEMBL6831983 | 0.78 | NOTCH1 (0.41) | GPR119MGLLUSP30NOTCH1PTPN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030203935-A1 | Cyanobiphenyl derivatives | TEIJIN LIMITED | 2003-10-30 | — | — | US | disclosed |
| US-6538137-B1 | Blood-coagulation factor X inhibitors | TEIJIN LIMITED (JP) | 2003-03-25 | — | — | US | disclosed |
| EP-1179527-A1 | CYANOBIPHENYL DERIVATIVES | TEIJIN LIMITED (JP) | 2002-02-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030203935-A1 | Cyanobiphenyl derivatives | F9, F12, F11 | GPR119 4007/4885MGLL 523/4885USP30 3106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.